{
 "drug": "Dacomitinib Tablet",
 "asOf": "2026-08-25",
 "status": "discontinuing",
 "since": "06/08/2026",
 "dayN": 78,
 "cat": "Oncology",
 "companies": [
  "Pfizer Inc."
 ],
 "reasons": [],
 "records": [
  {
   "discontinued_date": "06/08/2026",
   "update_type": "New",
   "initial_posting_date": "06/08/2026",
   "package_ndc": "0069-0197-30",
   "generic_name": "Dacomitinib Tablet",
   "contact_info": "800-533-4535",
   "related_info": "Discontinuation of the manufacture of the drug",
   "openfda": {
    "application_number": [
     "NDA211288"
    ],
    "brand_name": [
     "VIZIMPRO"
    ],
    "generic_name": [
     "DACOMITINIB"
    ],
    "manufacturer_name": [
     "Pfizer Laboratories Div Pfizer Inc"
    ],
    "product_ndc": [
     "0069-0197",
     "0069-1198",
     "0069-2299"
    ],
    "product_type": [
     "HUMAN PRESCRIPTION DRUG"
    ],
    "route": [
     "ORAL"
    ],
    "substance_name": [
     "DACOMITINIB"
    ],
    "rxcui": [
     "2058915",
     "2058922",
     "2058924",
     "2058926",
     "2058930",
     "2058932"
    ],
    "spl_id": [
     "3ffd0da1-5601-4ecc-a8fb-f484693cb4c5"
    ],
    "spl_set_id": [
     "4ab27d2f-e385-4e9c-b324-fa69c10b855a"
    ],
    "package_ndc": [
     "0069-0197-30",
     "0069-1198-30",
     "0069-2299-30"
    ],
    "unii": [
     "5092U85G58"
    ]
   },
   "update_date": "06/08/2026",
   "therapeutic_category": [
    "Oncology"
   ],
   "dosage_form": "Tablet",
   "presentation": "Vizimpro, Tablet, 15 mg (NDC 0069-0197-30)",
   "company_name": "Pfizer Inc.",
   "status": "To Be Discontinued"
  },
  {
   "discontinued_date": "06/08/2026",
   "update_type": "New",
   "initial_posting_date": "06/08/2026",
   "package_ndc": "0069-1198-30",
   "generic_name": "Dacomitinib Tablet",
   "contact_info": "800-533-4535",
   "related_info": "Discontinuation of the manufacture of the drug",
   "openfda": {
    "application_number": [
     "NDA211288"
    ],
    "brand_name": [
     "VIZIMPRO"
    ],
    "generic_name": [
     "DACOMITINIB"
    ],
    "manufacturer_name": [
     "Pfizer Laboratories Div Pfizer Inc"
    ],
    "product_ndc": [
     "0069-1198",
     "0069-0197",
     "0069-2299"
    ],
    "product_type": [
     "HUMAN PRESCRIPTION DRUG"
    ],
    "route": [
     "ORAL"
    ],
    "substance_name": [
     "DACOMITINIB"
    ],
    "rxcui": [
     "2058915",
     "2058922",
     "2058924",
     "2058926",
     "2058930",
     "2058932"
    ],
    "spl_id": [
     "3ffd0da1-5601-4ecc-a8fb-f484693cb4c5"
    ],
    "spl_set_id": [
     "4ab27d2f-e385-4e9c-b324-fa69c10b855a"
    ],
    "package_ndc": [
     "0069-0197-30",
     "0069-1198-30",
     "0069-2299-30"
    ],
    "unii": [
     "5092U85G58"
    ]
   },
   "update_date": "06/08/2026",
   "therapeutic_category": [
    "Oncology"
   ],
   "dosage_form": "Tablet",
   "presentation": "Vizimpro, Tablet, 30 mg (NDC 0069-1198-30)",
   "company_name": "Pfizer Inc.",
   "status": "To Be Discontinued"
  },
  {
   "discontinued_date": "06/08/2026",
   "update_type": "New",
   "initial_posting_date": "06/08/2026",
   "package_ndc": "0069-2299-30",
   "generic_name": "Dacomitinib Tablet",
   "contact_info": "800-533-4535",
   "related_info": "Discontinuation of the manufacture of the drug",
   "openfda": {
    "application_number": [
     "NDA211288"
    ],
    "brand_name": [
     "VIZIMPRO"
    ],
    "generic_name": [
     "DACOMITINIB"
    ],
    "manufacturer_name": [
     "Pfizer Laboratories Div Pfizer Inc"
    ],
    "product_ndc": [
     "0069-2299",
     "0069-0197",
     "0069-1198"
    ],
    "product_type": [
     "HUMAN PRESCRIPTION DRUG"
    ],
    "route": [
     "ORAL"
    ],
    "substance_name": [
     "DACOMITINIB"
    ],
    "rxcui": [
     "2058915",
     "2058922",
     "2058924",
     "2058926",
     "2058930",
     "2058932"
    ],
    "spl_id": [
     "3ffd0da1-5601-4ecc-a8fb-f484693cb4c5"
    ],
    "spl_set_id": [
     "4ab27d2f-e385-4e9c-b324-fa69c10b855a"
    ],
    "package_ndc": [
     "0069-0197-30",
     "0069-1198-30",
     "0069-2299-30"
    ],
    "unii": [
     "5092U85G58"
    ]
   },
   "update_date": "06/08/2026",
   "therapeutic_category": [
    "Oncology"
   ],
   "dosage_form": "Tablet",
   "presentation": "Vizimpro, Tablet, 45 mg (NDC 0069-2299-30)",
   "company_name": "Pfizer Inc.",
   "status": "To Be Discontinued"
  }
 ]
}